Analysis of Supply, Distribution, Demand, and Access Issues Associated with Immune Globulin Intravenous (IGIV)
Contents
IGIV Supply and Distribution - Key Findings
IGIV Demand - Key Fundings
IGIV Access Problems- Key Fundings
Issues in the Design and Implementation of Drug Formularies and Therapeutic Classes
As part of the Medicare Part D pharmacy benefit scheduled for implementation in 2006 by the Medicare Prescription Drug, Improvement, and Modernization Act (MMA), beneficiaries will have a choice of private plans administering the benefit.? Although plans are required to provide access to needed drugs, the law does not require plans to provide equa
Health Care in Transition: Technology Assessment in the Private Sector
Health Care in Transition:
Technology Assessment in the Private Sector
Prepared by:
Richard Rettig of the RAND Corporation
Office of the Assistant Secretary of Planning and Evaluation
Agency for Health Care Policy and Research.
July, 1996.
Prescription Drug Coverage, Spending, Utilization, and Prices
Prescription drugs play an ever-increasing role in modern medicine. New medications are improving health outcomes and quality of life, replacing surgery and other invasive treatments, and quickening recovery for patients who receive these treatments. As important as prescription drugs are, not everyone has access to them. The newest drugs are ofte
Updated Analyses of Trends in Use of Assistive Devices
Over the 20 year period 1984-2004, use of assistive devices by older Americans (age 65 and older)
residing in the community increased greatly. In 1984, 72% of chronically disabled older Americans
made some use of assistive devices, with or without additional human help to perform activities of
daily living (i.e., tasks such as bathing, dressing
astdevup.pdf
PDF 
Accelerating Adoption of Assistive Technology to Reduce Physical Strain among Family Caregivers of the Chronically Disabled Elderly Living at Home
This report examines and assesses the often overlooked potential of assistive technology (AT) to benefit unpaid family caregivers who assist chronically disabled elders living at home. Although research has identified benefits, only a handful of publicly-funded family caregiver support programs give much attention to enabling caregivers’ access
AccAdoAT.pdf
Expanding the Use of Generic Drugs
Dramatic growth in the use of generic drugs has generated substantial savings for American consumers. To examine how the Department of Health and Human Services (HHS) can encourage the use of generic drugs, the Assistant Secretary for Planning and Evaluation (ASPE) examined barriers to, and opportunities for, expanding the use of generic drugs.
ib.pdf
Medicaid Contracts with Medicare Special Needs Plans Reflect Diverse State Approaches to Dually Eligible Beneficiaries
This paper is the third in a series on SNPs and their relationship to Medicaid. In the second paper of the series, we identified all states which had some kind of contractual relationship with SNPs prior to MIPPA, and classified those relationships into broad categories. The purpose of this third paper is to examine in greater detail a select grou
SNPdual.pdf
Economic Analysis of Availability of Follow-on Protein Products
Unlike most conventional drugs, biological products are usually large, complex molecules that are produced by living organisms. These commercially engineered biologics currently account for billions of dollars in health care spending. Starting early last century, Congress has regulated most biologics separately from small molecules under the Bio
report.pdf
Federal Authority for Medicare Special Needs Plans and their Relationship to State Medicaid Programs
This Brief reviews the history and current status of federal special needs plans (SNPs) authority, with particular attention to provisions of interest to state Medicaid programs that have or are considering entering into contracts with SNPs to integrate or coordinate Medicaid long-term care services with Medicare primary, acute and prescription dr
leghist.pdf
Evaluation of New Measures of Assistive Technology and the Home Environment from the 2005 Pilot Study of Technology and Aging
The purpose of this report is to highlight the analytic properties of the assistive technology and environment measures in the final recommended module. The authors address three distinct but complimentary questions: (1) How do questions that combine several environmental features or devices (global measures) compare with more detailed items? (2)
newmeas.pdf
Cost Effectiveness Considerations in the Approval and Adoption of New Health Technologies
The Office of the Assistant Secretary for Planning and Evaluation (ASPE) commissioned The Lewin Group (Lewin) to determine how and to what extent cost-effectiveness (CE) considerations are incorporated in the approval and adoption of new health technologies and the implications of not incorporating such considerations. This report examines the use
report.pdf
Understanding Variations in International Drug Prices
Rapidly rising prescription drug prices have caused many consumers, third-party payers, and policymakers to look for ways to lower their drug costs. One strategy that many have seen as a potential solution is to import drug products from countries where drug prices are lower than those in the United States commonly called reimportation.
report.pdf
Drug Use and Spending for Medicare Beneficiaries During Part A Qualifying Skilled Nursing Facility Stays and Non-Qualifying Long-Term Care Facility Stays
This Policy Brief helps fill an important gap in our understanding of medication patterns in long-term care facilities (LTCFs) by comparing use and spending for prescription and over-the-counter drugs during skilled nursing facility (SNF) stays and related non-qualifying long-term care facility episodes. Its first aim is to characterize Medicare-
druguse.pdf
A National Comparison of Prescription Drug Expenditures by Medicare Beneficiaries Living in the Community and Long-Term Care Facility Settings
This Policy Brief provides a snapshot of prescription drug use and spending in 2001, the latest year for which complete community and long-term care facility drug data are available. For this analysis, the authors present summary findings of: (1) characteristics of Medicare beneficiaries residing in long-term care facilities and the community; (2)
pdnatcom.pdf
National Estimates of Prescription Drug Utilization and Expenditures in Long-Term Care Facilities
This Policy Brief offers an updated look at prescription drug utilization by Medicare beneficiaries residing in long-term care facilities and reports, for the first time, national estimates of prescription drug spending by this population. [23 PDF pages]
pdnatest.pdf
Prescription Drug Spending by Medicare Beneficiaries in Institutional and Residential Settings, 1998-2001
This study had three specific aims: (1) To prepare nationally-representative estimates of drug spending in long-term care (LTC) facilities; (2) To compare drug use and spending for beneficiaries in LTC facilities versus beneficiaries in the community; and (3) To examine medication use and spending by short-stay skilled nursing home facility reside
pdspend.pdf
Analysis of Supply, Distribution, Demand, and Access Issues Associated with Immune Globulin Intravenous (IGIV)
IGIV is a plasma product that is used to treat patients with immune system disorders. A significant percentage of IGIV use is for off-label indications. Current conditions in the IGIV industry and market are complex and rapidly evolving. The growing demand for IGIV, supply capacity issues, changes in reimbursement, and the relocation of sites of s
report.pdf
An Overview of the US Health System Chart Book
This chart book provides data on various aspects of the US health system including public and private health care coverage, provider data, and international comparisons of the US to OECD countries. [128 PDF pages]
report.pdf